Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LIXTW 
Lixte Biotechnology Holdings Inc (LIXTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LIXTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.49M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 793 | Beta 0.19 | 52 Weeks Range 0.02 - 0.09 | Updated Date 03/29/2025 |
52 Weeks Range 0.02 - 0.09 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.88% | Return on Equity (TTM) -148.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 2411936 |
Shares Outstanding - | Shares Floating 2411936 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lixte Biotechnology Holdings Inc
Company Overview
History and Background
Lixte Biotechnology Holdings, Inc. (LIXT) was founded in 2005. It is a pharmaceutical company focused on developing innovative cancer therapies, primarily using protein phosphatase inhibitors to target cellular metabolism and growth.
Core Business Areas
- Drug Development: Focuses on the research, development, and commercialization of new chemical entities (NCEs) for the treatment of cancer and other diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Secures and manages patents and other intellectual property rights related to its technologies.
Leadership and Structure
Dr. John S. Kovach serves as the CEO. The company has a board of directors overseeing its strategic direction and management team.
Top Products and Market Share
Key Offerings
- LB-100 series: The LB-100 series is Lixte's most advanced product candidate, a first-in-class protein phosphatase inhibitor, in Phase 2 clinical trials for various cancers, as well as potential for Alzheimer's. Market share data is unavailable. Competitors include other companies developing similar targeted therapies, particularly in the kinase inhibitor space. Main companies competing in cancer treatments include Merck (MRK), Johnson & Johnson (JNJ), and Pfizer (PFE).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive. It involves significant regulatory hurdles and high costs for drug development and approval. The cancer therapy market is growing due to aging populations and advancements in understanding cancer biology.
Positioning
Lixte Biotechnology is positioned as a clinical-stage biotechnology company focusing on innovative cancer therapies. Its competitive advantage lies in its unique protein phosphatase inhibition technology.
Total Addressable Market (TAM)
The global cancer therapeutics market is expected to reach hundreds of billions of dollars. Lixte's positioning is in the niche area of phosphatase inhibitors, aiming to capture a small but significant portion of this TAM through successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Promising preclinical and clinical data
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on single drug candidate (LB-100 series)
- High regulatory risk
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion of therapeutic indications for LB-100 series
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory setbacks
Competitors and Market Share
Key Competitors
- MRK
- JNJ
- PFE
- BMY
Competitive Landscape
Lixte faces intense competition from larger, established pharmaceutical companies with greater resources and broader pipelines. Its advantage lies in its novel therapeutic approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its status as a clinical-stage company. Growth depends on successful clinical milestones.
Future Projections: Future growth is highly uncertain and depends on successful clinical trials and commercialization. Analyst estimates are limited due to the speculative nature of the company.
Recent Initiatives: Focus on advancing LB-100 series through Phase 2 clinical trials, and exploring potential partnerships.
Summary
Lixte Biotechnology is a high-risk, high-reward clinical-stage company with a novel therapeutic approach. Its success hinges on the outcome of its clinical trials for the LB-100 series. The company faces significant financial and regulatory hurdles, along with intense competition from larger players. They are a promising candidate for cancer treatment but rely heavily on future success of the LB-100 series. Close monitoring of clinical trials and financial stability are key.
Similar Companies
- MRK
- JNJ
- PFE
- BMY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (limited)
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and may be subject to change. Investing in biotechnology companies involves substantial risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lixte Biotechnology Holdings Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2020-11-25 | President, CEO & Chairman of the Board of Directors Mr. Bastiaan van der Baan M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://lixte.com |
Full time employees 2 | Website https://lixte.com | ||
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.